Placebo and modafinil effect on sleepiness in obstructive sleep apnea

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 552-559

  Bittencourt, Lia Rita A ^a   Lucchesi, Ligia M ^a   Rueda, Adriana D ^a   Garbuio, Silvério A ^a   Palombini, Luciana O ^a   Guilleminault, Christian ^b   Tufik, Sergio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b STANFORD UNIVERSITY   (United States)

Author keywords

CPAP; Epworth Sleepiness Scale (ESS); Modafinil; Obstructive sleep apnea syndrome (OSAS); Placebo effect; Residual sleepiness

Indexed keywords

MODAFINIL;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP APNEA SYNDROME; SOMNOLENCE; STOMACH PAIN; WAKEFULNESS;

BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COMBINED MODALITY THERAPY; COMORBIDITY; CONTINUOUS POSITIVE AIRWAY PRESSURE; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REACTION TIME; SINGLE-BLIND METHOD; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 38749122856     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.10.016     Document Type: Article

References (38)

1. American Academy of Sleep Medicine. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 22 (1999) 667-689
2. American Sleep Disorders Association. Atlas Task Force - EEG arousals: scoring rules and examples. Sleep 15 (1992) 174-184
3. American Sleep Disorders Association. Atlas Task Force - recording and scoring leg movements. Sleep 16 (1993) 749-759
4. Arnulf I., Homeyer P., Garma L., Whitelaw W.A., and Derenne J.P. Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration 64 (1997) 159-161
5. Beusterien K.M., Rogers A.E., Walsleben J.A., Emsellem H.A., Reblando J.A., Wang L., et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22 (1999) 757-765
6. Black J.E., and Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 18 (2005) 464-471
7. Damian M.S., Gerlach A., Schmidt F., Lehmann E., and Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 56 (2001) 794-796
8. Dinges D.F., and Weaver T.E. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 4 (2003) 393-402
9. Endeshaw Y. Clinical characteristics of obstructive sleep apnea in community-dwelling older adults. J Am Geriatr Soc 54 (2006) 1700-1704
10. Ferraro L., Tanganelli S., O'Connor W.T., Antonelli T., Rambert F., and Fuxe K. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220 (1996) 5-8
11. Ferraro L., Tanganelli S., O'Connor W.T., Antonelli T., Rambert F., and Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 306 (1996) 33-39
12. Ferraro L., Antonelli T., Tanganelli S., O'Connor W.T., Perez de la Mora M., Mendez-Franco J., et al. The vigilance promoting drug modafinil increased extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 20 (1999) 346-356
13. Ferraro L., Fuxe K., Tanganelli S., Fernandez M., Rambert F.A., and Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 39 (2000) 1974-1983
14. Guilleminault C., and Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep 19 (1996) 117-122
15. Guilleminault C., Aftab F.A., Karadeniz D., Philip P., and Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol 7 (2000) 381-384
16. Guy W. ECDEU assessment manual for psychopharmacology vol. 165 (1976), National Institute of Mental Health, US Dept. of Health, Education, and Welfare, Washington, DC 773-780
17. Heitman S.J., and Flemons W.W. Evidence-based medicine and sleep apnea. Respir Care 46 (2001) 1418-1434
18. Heitmann J., Cassel W., Grote L., Bickel U., Hartlaub U., Penzel T., et al. Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea?. Clin Pharmacol Ther 65 (1999) 328-335
19. Hogl B., Saletu M., Brandauer E., Glatzl S., Frauscher B., Seppi K., et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25 (2002) 905-909
20. Jasinski D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14 (2000) 53-60
21. Jasinski D.R., and Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 23 (2000) 149-156
22. Jenkinson C., Davies R.J.O., Mullins R., and Stradling J.R. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 19 (1999) 2100-2105
23. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991) 540-545
24. Karrer W., Rothe T.B., Ryckx A., and Keller U. Nasal CPAP therapy in obstructive sleep apnea syndrome: patient compliance. Schweiz Med Wochenschr 130 (2000) 1291-1297
25. Kingshott R.N., Vennelle M., Coleman E.L., Engleman H.M., Mackay T.W., and Douglas N.J. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 163 (2001) 918-923
26. Krieger J., McNicholas W.T., Levy P., De Backer W., Douglas N., Marrone O., et al. Public Health and medicolegal implications of sleep apnoea. Eur Respir J 20 (2002) 1594-1609
27. McHorney C.A., Ware Jr. J.E., and Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31 (1993) 247-263
28. Pack A.I., Black J.E., Schwartz J.R.L., and Matheson J.K. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 164 (2001) 1675-1681
29. Panckeri K.A., Schotland H.M., Pack A.I., and Hendricks J.C. Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. Sleep 19 (1996) 626-631
30. Rammohan M., Kalantar-Zadeh K., Liang A., and Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 15 (2005) 345-355
31. Rechtschaffen A., and Kales A. A manual of standardized technology, techniques and scoring system for sleep stages of human subjects (1968), Brain Information Service/Brain Research Institute, UCLA, Los Angeles, California
32. Roth T., White D., Schmidt-Nowara W., Wesnes K.A., Niebler G., Arora S., et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 28 (2006) 689-706
33. Sangal R.B., Thomas L., and Mitler M.M. Maintenance of wakefulness test and multiple sleep latency test. Measurement of different abilities in patients with sleep disorders. Chest 101 (1992) 898-902
34. Scammell T.E., Estabrooke I.V., McCarthy M.T., Chemelli R.M., Yanagisawa M., Miller M.S., et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20 (2000) 8620-8628
35. Schwartz J.R., Hirshkowitz M., Erman M.K., and Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 124 (2003) 2192-2199
36. Talbot K., Stradling J., Crosby J., and Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 13 (2003) 357-364
37. US Modafinil In Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 54 (2000) 1166-1175
38. Young T., Peppard P.E., and Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perpective. AM J Respir Crit Care Med 165 (2002) 1217-1239